Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member printed grouped question UIN question first answered answering member label attachment file name title
tabling member	label

Search

1361539

	registered interest
	date	19/10/2021
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Liothyronine
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what steps NHS Clinical Commissioners took to communicate national guidance for the prescribing of liothyronine to local NHS bodies; and whether that guidance says that liothyronine may only be prescribed when recommended by a specialist after treatment using levothyroxine has failed.
	tabling member printed	Lord Hunt of Kings Heath
	uin	HL3197
	answer	answer is ministerial correction date of answer 29/10/2021 answer text <p>National Health Service clinical commissioners have promoted national guidance through their bulletins with clinical commissioning groups members. National guidance recommends that in circumstances where levothyroxine has failed, endocrinologists providing NHS services may recommend liothyronine for individual patients after a carefully audited trial of liothyronine for at least three months duration.</p><p>We have made no assessment on whether liothyronine should be de-classified as a high cost medicine. To date, NHS England NHS Improvement have not conducted any specific assessments on liothyronine following the Competition and Markets Authority ruling. This will be considered as part of any formal review to national guidance.</p> answering member printed Lord Kamall grouped question UIN HL3198 question first answered 29/10/2021 09:52:10 answering member 4909 label Biography information for Lord Kamall
	tabling member	2024 label Biography information for Lord Hunt of Kings Heath

1361540

	registered interest
	date	19/10/2021
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Liothyronine
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what assessment they have made of whether liothyronine should be declassified as a high-cost medicine following the Competition and Markets Authority ruling and fine issued to Advanz for artificially inflating the price of thyroid tablets.
	tabling member printed	Lord Hunt of Kings Heath
	uin	HL3198
	answer	answer is ministerial correction date of answer 29/10/2021 answer text <p>National Health Service clinical commissioners have promoted national guidance through their bulletins with clinical commissioning groups members. National guidance recommends that in circumstances where levothyroxine has failed, endocrinologists providing NHS services may recommend liothyronine for individual patients after a carefully audited trial of liothyronine for at least three months duration.</p><p>We have made no assessment on whether liothyronine should be de-classified as a high cost medicine. To date, NHS England NHS Improvement have not conducted any specific assessments on liothyronine following the Competition and Markets Authority ruling. This will be considered as part of any formal review to national guidance.</p> answering member printed Lord Kamall grouped question UIN HL3197 question first answered 29/10/2021 09:52:10 answering member 4909 label Biography information for Lord Kamall
	tabling member	2024 label Biography information for Lord Hunt of Kings Heath

1361541

	registered interest
	date	19/10/2021
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Liothyronine
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government whether they will conduct a review of (1) the actions of NHS England, and (2) the impact on patients with thyroid conditions, following the Competition and Markets Authority’s ruling and fine issued to Advanz for artificially inflating the price of thyroid tablets.
	tabling member printed	Lord Hunt of Kings Heath
	uin	HL3199
	answer	answer is ministerial correction date of answer 29/10/2021 answer text <p>We have no plans to do so. NHS England and NHS Improvement’s guidance Items which should not routinely be prescribed in primary care: Guidance for CCGs identifies items which are clinically effective but where more cost-effective products are available. This includes liothyronine and other products that have been subject to excessive price inflation.</p><p>The guidance states that there are three categories for such items which are as follows:</p><p>- Products of low clinical effectiveness, where there is a lack of robust evidence of clinical effectiveness or there are significant safety concerns;</p><p>- Products which are clinically effective but where more cost-effective products are available, including some products that have been subject to excessive price inflation; and</p><p>- Products which are clinically effective but due to the nature of the product are deemed a low priority for National Health Service funding.</p><p> </p><p>Liothyronine was included in the second category. Additionally, it was noted that there was limited evidence to support its routine prescribing in preference to levothyroxine. A copy of this guidance is attached. NHS England and NHS Improvement will review the guidance on a regular basis to ensure that any updated evidence on clinical and cost effectiveness is considered.</p> answering member printed Lord Kamall question first answered 29/10/2021 09:55:14 answering member 4909 label Biography information for Lord Kamall attachment 1 file name HL3199 - Attachment 2.pdf title Items which should not routinely be prescribed in
	tabling member	2024 label Biography information for Lord Hunt of Kings Heath

1581667

	registered interest
	date	30/01/2023
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Liothyronine
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask His Majesty's Government what cost assessment they have undertaken of the daily dose rationing of liothyronine regardless of clinical need by the (1) NHS Devon, (2) NHS Buckinghamshire, and (3) NHS Hertfordshire, Integrated Care Boards; and what comparative assessment they have made of (a) the NHS England national guidance, and (b) the National Institute for Health and Care Excellence British National Formulary guidance on liothyronine, given the risk of harm to patients and that smaller doses lead to higher costs.
	tabling member printed	Lord Hunt of Kings Heath
	uin	HL5206
	answer	answer is ministerial correction date of answer 09/02/2023 answer text <p>No assessments have been made.</p> answering member printed Lord Markham question first answered 09/02/2023 12:17:34 answering member 4948 label Biography information for Lord Markham
	tabling member	2024 label Biography information for Lord Hunt of Kings Heath